Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Jens Huober, MD1,2; Carlos H. Barrios, MD3; Naoki Niikura, MD, PhD4; Michał Jarząb, MD, PhD5; Yuan-Ching Chang, MD, PhD6; Shannon L. Huggins-Puhalla, MD7; José Pedrini, MD, PhD8; Lyudmila Zhukova, MD, PhD9; Vilma Graupner, PhD10; Daniel Eiger, MD10; Volkmar Henschel, PhD11; Nino Gochitashvili, MD, PhD12; Chiara Lambertini, PhD13; Eleonora Restuccia, MD14; and Hong Zhang, MD, PhD14; the IMpassion050 Trial Investigators

abstract

PURPOSE Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)–positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients.

METHODS Patients with a primary tumor of > 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0) were randomly assigned 1:1 to atezolizumab/placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel, and PH. After surgery, patients were to continue atezolizumab/placebo and PH (total: 1 year of HER2-targeted therapy); those with residual disease could switch to ado-trastuzumab emtansine with atezolizumab/placebo. Coprimary efficacy end points were pathologic complete response (pCR; ypT0/is ypN0) rates in intention-to-treat (ITT) and programmed cell death-ligand 1 (PD-L1)–positive populations.

RESULTS At clinical cutoff (February 5, 2021), pCR rates in the placebo and atezolizumab groups in the ITT populations were 62.7% (n = 143/228) and 62.4% (n = 141/226), respectively (difference –0.33%; 95% CI, –9.2 to 8.6; P = .9551). The pCR rates in the placebo and atezolizumab groups in patients with PD-L1–positive tumors were 72.5% (n = 79/109) and 64.2% (n = 70/109), respectively (difference –8.26%; 95% CI, –20.6 to 4.0; P = .1846). Grade 3-4 and serious adverse events were more frequent in the atezolizumab versus placebo group. Coprimary efficacy end points were pathologic complete response (pCR; ypT0/is ypN0) rates in intention-to-treat (ITT) and programmed cell death-ligand 1 (PD-L1)–positive populations.

CONCLUSION Atezolizumab with neoadjuvant dose-dense doxorubicin/cyclophosphamide–paclitaxel and PH for high-risk, HER2-positive early breast cancer did not increase pCR rates versus placebo in the ITT or PD-L1–positive populations. PH and chemotherapy remains standard of care; longer follow-up may help to inform the long-term impact of atezolizumab.

INTRODUCTION

Human epidermal growth factor receptor 2 (HER2), overexpressed in approximately 15%-20% of breast carcinomas, conferred a more aggressive phenotype and poorer patient outcomes.1,2 However, the HER2-targeted therapies pertuzumab and trastuzumab (PH) have substantially improved patient prognosis in early and metastatic disease.3,4 In high-risk (tumor > 2 cm/node-positive), HER2-positive early breast cancer (EBC), neoadjuvant/adjuvant PH (total of 1 year) and chemotherapy is standard of care (SOC).5–9 Pathologic complete response (pCR) is associated with significantly improved long-term outcomes in HER2-positive breast cancer (BC).10,11 Patients with residual disease in the breast and/or axilla or at an initially advanced, clinical stage are at increased risk of recurrence or death.12 For patients with residual disease following neoadjuvant therapy, ado-trastuzumab
Atezolizumab in HER2-Positive Early Breast Cancer

CONTEXT

Key Objective
Can addition of atezolizumab to neoadjuvant standard of care (pertuzumab and trastuzumab [PH], and chemotherapy) improve outcomes in high-risk, human epidermal growth factor receptor 2–positive early breast cancer? To our knowledge, IMpassion050 was the first study to assess this question.

Knowledge Generated
Compared with placebo plus PH and chemotherapy, atezolizumab plus PH and chemotherapy was not superior with regards to pathologic complete response rate, both in the intention-to-treat and programmed cell death-ligand 1–positive population. The overall safety profile was consistent with that observed in other combination studies of atezolizumab.

Relevance
These findings highlight the validity of PH and chemotherapy in human epidermal growth factor receptor 2–positive early breast cancer, but longer follow-up of IMpassion050 is required to inform the long-term role of cancer immunotherapy, such as atezolizumab, in this setting.

METHODS

Study Design and Patients
Patients were ≥ 18 years old with a primary tumor of ≥ 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0), an Eastern Cooperative Oncology Group performance status of 0/1, and a left ventricular ejection fraction of ≥ 55%. Key exclusion criteria were prior history of invasive BC, stage IV BC, prior systemic therapy for BC, or prior anthracyclines or taxanes for any malignancy. HER2-positivity, PD-L1 status, hormone receptor status, and PIK3CA mutation status were assessed centrally.

Eligible patients were randomly assigned 1:1 using a permutated-block method to receive intravenous (IV) atezolizumab or placebo, with neoadjuvant dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel and PH (ddAC-PacPH; Data Supplement, online only). Random assignment was stratified by tumor stage at diagnosis (T2 v T3-4), hormone receptor status (estrogen receptor–positive and/or progesterone receptor–positive), and HER2 status. To improve outcomes for high-risk, HER2-positive EBC, we report the primary analysis.

On June 4, 2019, the Protocol (online only) was amended to be powered for the primary end point of pCR in the PD-L1–positive population, in addition to the intention-to-treat (ITT) population, because of the potential predictive value of PD-L1 expression for clinical benefit with atezolizumab.

The target sample size was thus increased from 224 to 453 patients.

Study Oversight
IMpassion050 was designed by the senior academic authors and representatives of the sponsor (F. Hoffmann-La Roche Ltd, Basel, Switzerland). Data were collected by the sponsor and analyzed in collaboration with the senior academic authors, who vouched for the completeness and accuracy of the data and analyses, and for the fidelity of the study to the protocol. IMpassion050 was performed in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee for every site. Every patient provided written informed consent.
Study Procedures

During the neoadjuvant phase, patients received, once every 2 weeks for four cycles, IV atezolizumab 840 mg or placebo, and IV doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (ddAC) and myeloid growth factor support according to local guidelines. This was followed by four cycles of atezolizumab/placebo (1,200 mg IV once every 3 weeks), paclitaxel (80 mg/m² IV once weekly), trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). In the adjuvant phase, patients continued atezolizumab/placebo with PH to complete 1 year of HER2-targeted therapy. Patients with residual disease at surgery could switch to ado-trastuzumab emtansine (3.6 mg/kg IV once every 3 weeks for 14 cycles), while maintaining atezolizumab/placebo. After review of unblinded safety and efficacy on January 26, 2021, the independent Data Monitoring Committee (iDMC) recommended stopping randomized atezolizumab/placebo treatment because of an unfavorable benefit-risk profile, with patients continuing SOC through the completion of their adjuvant treatment per study protocol. To reflect this, the protocol and informed consent form were subsequently amended (see the Data Supplement for major changes to the protocol from version to version).

HER2-positive status was assessed with US Food and Drug Administration–approved tests, either as an immunohistochemistry (IHC) 3+ score (PATHWAY anti-HER2/neu [4B5] assay; Ventana Medical Systems, Inc, Tucson, AZ), or as a HER2 gene amplification (ratio ≥ 2) by in situ hybridization (ISH; INFORM HER2 dual ISH assay; Ventana Medical Systems, Inc). PD-L1 status was assessed by IHC (VENTANA SP142 antibody test; Ventana Medical Systems, Inc).

PIK3CA mutation status was assessed using the cobas PIK3CA Mutation Test (Roche Molecular Diagnostics, Pleasanton, CA) and cobas 4800 System (Roche Molecular Diagnostics), as described previously.23

Study End Points

The coprimary end points were pCR rates (ypT0/is ypN0) in the ITT and PD-L1–positive populations. Secondary end points included pCR in patients with PD-L1–negative tumors, event-free survival (EFS), and safety. EFS was defined as the time from random assignment to the first documented disease recurrence, unequivocal tumor progression determined by the treating investigator, or death.
Severity of adverse events (AEs) was graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0.24

Statistical Analysis

The ITT population comprised all randomly assigned patients, whether or not the assigned study treatment was received. The safety population comprised patients who received any amount of any study drug.

The planned sample size was 453 patients (40% predicted to have PD-L1–positive tumors). In the population with PD-L1–positive tumors, this enabled 80% power to detect a pCR improvement from 65% to 83% in the atezolizumab group at a 4.8% significance level (two-sided), assuming a dropout rate of 7%. Patients with a missing pCR assessment were counted as not achieving a pCR. In the ITT population, the sample size enabled 82.8% power to detect an improvement from 54% to 72% at a 0.2% two-sided significance level, assuming a dropout rate of 10%. pCR treatment comparisons were made using Cochran-Mantel-Haenszel tests, stratified according to the factors used at random assignment. CIs for pCR differences between groups were determined using the normal approximation to the binomial distribution. Hazard ratios for EFS were estimated using a Cox proportional hazards model. A

### TABLE 1. Baseline Demographics and Disease Characteristics in the ITT Population

| Patient Demographic or Characteristic | Placebo Plus ddAC-PacPH (n = 228) | Atezolizumab Plus ddAC-PacPH (n = 226) |
|--------------------------------------|-----------------------------------|--------------------------------------|
| Age | Median, years 50.0 | 50.0 |
| | < 65, No. (%) 207 (90.8) | 204 (90.3) |
| | ≥ 65, No. (%) 21 (9.2) | 22 (9.7) |
| Sex, No. (%) | Female 227 (99.6) | 225 (99.6) |
| | Male 1 (0.4) | 1 (0.4) |
| Race, No. (%) | White 142 (62.3) | 149 (65.9) |
| | Asian 66 (28.9) | 62 (27.4) |
| | Black or African American 13 (5.7) | 8 (3.5) |
| | American Indian or Alaska Native 1 (0.4) | 1 (0.4) |
| | Multiple or unknown 6 (2.6) | 6 (2.7) |
| ECOG performance status, No. (%) | 0 215 (94.3) | 215 (95.1) |
| | 1 13 (5.7) | 11 (4.9) |
| Staging of primary tumor, No. (%) | T2 151 (66.2) | 150 (66.4) |
| | T3-4 77 (33.8) | 76 (33.6) |
| Staging of regional lymph nodes, No. (%) | N1 157 (68.9) | 169 (74.8) |
| | N2 46 (20.2) | 38 (16.8) |
| | N3 25 (11.0) | 19 (8.4) |
| Central hormone receptor status, No. (%) | ER-positive and/or PgR-positive 117 (51.3) | 116 (51.3) |
| | ER-negative and PgR-negative 111 (48.7) | 110 (48.7) |
| Central PD-L1 status,* No. (%) | IC 0 (negative) 119 (52.2) | 116 (51.3) |
| | IC 1/2/3 (positive) 109 (47.8) | 110 (48.7) |
| Central HER2 status by IHC, No. (%) | 0 1 (0.4) | 0 |
| | 1+ 1 (0.4) | 2 (0.9) |
| | 2+ 23 (10.1) | 18 (8.0) |
| | 3+ 201 (88.2) | 204 (90.3) |
| | Unknown 2 (0.9) | 2 (0.9) |

### TABLE 1. Baseline Demographics and Disease Characteristics in the ITT Population (continued)

| Patient Demographic or Characteristic | Placebo Plus ddAC-PacPH (n = 228) | Atezolizumab Plus ddAC-PacPH (n = 226) |
|--------------------------------------|-----------------------------------|--------------------------------------|
| Central HER2 status by ISH, No. (%) | Positive 223 (97.8) | 212 (93.8) |
| | Negative 1 (0.4) | 0 |
| | Unknown 4 (1.8) | 14 (6.2) |
| Central PIK3CA mutational status, No. (%) | Mutated 61 (26.8) | 67 (29.6) |
| | Wild-type 155 (68.0) | 150 (66.4) |
| | Missing 12 (5.3) | 9 (4.0) |

Abbreviations: ddAC, dose-dense doxorubicin and cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; H, trastuzumab; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; ITT, intention-to-treat; N, nodal stage; P, pertuzumab; Pac, paclitaxel; PD-L1, programmed cell death-ligand 1; PD-L1 IC, PD-L1–expressing tumor-infiltrating immune cells as percentage of tumor area; PgR, progesterone receptor; T, tumor stage.

Some samples could only be matched to patients following random assignment, which led to a change in PD-L1 status for one patient. The efficacy analyses used the PD-L1 status assigned at random assignment.

from any cause, whichever occurred first. Severity of adverse events (AEs) was graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0.24

Statistical Analysis

The ITT population comprised all randomly assigned patients, whether or not the assigned study treatment was received. The safety population comprised patients who received any amount of any study drug.

The planned sample size was 453 patients (40% predicted to have PD-L1–positive tumors). In the population with PD-L1–positive tumors, this enabled 80% power to detect a pCR improvement from 65% to 83% in the atezolizumab group at a 4.8% significance level (two-sided), assuming a dropout rate of 7%. Patients with a missing pCR assessment were counted as not achieving a pCR. In the ITT population, the sample size enabled 82.8% power to detect an improvement from 54% to 72% at a 0.2% two-sided significance level, assuming a dropout rate of 10%. pCR treatment comparisons were made using Cochran-Mantel-Haenszel tests, stratified according to the factors used at random assignment. CIs for pCR differences between groups were determined using the normal approximation to the binomial distribution. Hazard ratios for EFS were estimated using a Cox proportional hazards model. A
predefined unstratified pCR subgroup analysis was conducted for the ITT and PD-L1-positive populations. Safety analyses were descriptive.

RESULTS

Study Population

Patients were enrolled from January 2019 to August 2020; 454 patients (228 with placebo and 226 with atezolizumab; Fig 1) were randomly assigned across 73 sites in 12 countries. At clinical cutoff (February 5, 2021), 202 patients were on active treatment (44.5%), 228 were in follow-up (50.2%), 24 had discontinued from the study (5.3%), and three were yet to undergo surgery (Fig 1). Median duration of follow-up was 15.9 (placebo) and 15.7 (atezolizumab) months.

Baseline demographics and disease characteristics were balanced between groups (Table 1).

Efficacy

pCR rates in the ITT population were 62.7% (n = 143/228) with placebo and 62.4% (n = 141/226) with atezolizumab (difference –0.33%; 95% CI, –9.23 to 8.57; P = .9551; Fig 2A). pCR rates in the PD-L1–positive population were 72.5% (n = 79/109) and 64.2% (n = 70/109) with placebo and atezolizumab, respectively (difference –8.26%; 95% CI, –20.56 to 4.04; P = .1846; Fig 2A). The results were consistent across subgroups both in the ITT (Fig 2B) and PD-L1–positive (Data Supplement) populations, on the basis of age, race, tumor and nodal staging, and biomarkers, including central HER2, hormone receptor, and PIK3CA mutational status. In patients with PD-L1–negative tumors (secondary end point), pCR rates were 53.8% (n = 64/119) with placebo and 60.7% (n = 71/117) with atezolizumab (difference 6.90%; 95% CI, –5.69 to 19.49; Fig 2A).

Seven patients (3.1%) in the placebo group had an EFS event compared with 12 (5.3%) in the atezolizumab group (Data Supplement; P = .2084); median EFS was not estimable in either group. Overall, 13/19 (68.4%) events were disease recurrences, five were fatal AEs, and one was death due to gastric cancer. There was no disease progression during neoadjuvant treatment.

Safety

In the neoadjuvant phase, exposure to study drugs did not differ between groups (Data Supplement). The overall incidence of serious AEs, grade 3-4 AEs, and AEs of special interest (AESIs) for atezolizumab was increased in the atezolizumab compared with the placebo group (Table 2). There were similar rates of AEs leading to any study treatment withdrawal between groups (Table 2). Grade 5 AEs were imbalanced in the neoadjuvant phase, with four in the atezolizumab group (alveolitis, septic shock, sepsis, and COVID-19) versus none in the placebo group; two of these fatal AEs (alveolitis and septic shock) were attributed by the investigator to study treatment (Table 3). The grade 5 alveolitis, related to ddAC and atezolizumab, occurred in an 81-year-old patient admitted to hospital because of a traumatic vertebral fracture complicated by pneumonia with suspected pulmonary metastasis. The grade 5 septic shock, related to paclitaxel, PH, and atezolizumab, occurred in a 61-year-old patient with type 2 diabetes and urinary tract infection, aggravated by severe neutropenia. Sepsis also occurred in a 69-year-old patient, caused by relapsed anal fistula leading to perineal ulceration and vulvar infection (in the absence of severe neutropenia).

DISCUSSION

To our knowledge, IMpassion050 is the first phase III study to report data on cancer immunotherapy in HER2–positive EBC. pCR rates with PH and chemotherapy were high and in accordance with study expectations; however, addition of atezolizumab did not increase pCR rates versus placebo in the ITT or PD-L1–positive populations. When the iDMC recommended stopping randomized atezolizumab/placebo treatment because of an unfavorable benefit-risk profile,
**FIG 2.** (A) pCR in the ITT (primary end point), PD-L1–positive (primary end point), and PD-L1–negative (secondary end point) populations, and (B) pCR in subgroups of the ITT population. *Stratified (Cochran-Mantel-Haenszel test). *ISH-positive/IHC 0/1+: number of pCR events in placebo/atezolizumab: n = 0/2 versus n = 0/2. ISH-positive/IHC unknown: n = 1/2 versus n = 2/2. ISH-negative/IHC 3+: n = 1/1 versus n = 0/0. 1HIC 0/1+: number of pCR events in placebo/atezolizumab: n = 0/2 versus n = 0/2. IHC unknown: n = 1/2 versus n = 2/2. 2Patients whose tumor test results were IHC 2+ had ISH-positive status. *ISH-negative: number of pCR events in placebo/atezolizumab: n = 1/1 versus n = 0/0. ISH-unknown: n = 1/4 versus n = 10/14. *PIK3CA missing: number of pCR events in placebo/atezolizumab: n = 14/21 versus n = 11/20. ddAC, dose-dense doxorubicin and cyclophosphamide; ER, estrogen receptor; H, trastuzumab; IHC, immunohistochemistry; ISH, in situ hybridization; ITT, intention-to-treat; N, nodal stage; NE, not estimable; P, pertuzumab; Pac, paclitaxel; pCR, pathologic complete response (ypT0/is ypN0); PD-L1, programmed cell death-ligand 1; PgR, progesterone receptor; T, tumor stage.
only three patients were yet to undergo surgery at clinical cutoff (February 5, 2021). Thus, the assessment of the coprimary end point of pCR in the ITT and PD-L1–positive populations was not affected by the iDMC recommendation.

Preclinical data provide a strong rationale for combining cancer immunotherapy with HER2-targeted therapy in HER2-positive BC. The lack of pCR improvement with atezolizumab in IMpassion050 is surprising, given the expected greater benefit of cancer immunotherapy in EBC compared with the advanced setting, because of a lower tumor burden, reduced immune escape mechanisms, and a more efficient immune system in patients with EBC. Treatment exposure is unlikely to explain the lack of pCR benefit seen with atezolizumab, as exposure to chemotherapy/HER2-targeted therapy was not compromised by adding atezolizumab. Although achieving a pCR has been associated with significantly improved long-term outcomes (eg, EFS, overall survival [OS]) in patients with HER2-positive EBC receiving neoadjuvant anti–HER2-based therapy, there may be a long-term impact of cancer immunotherapy even with no pCR improvement, given the time required for cancer immunotherapy to exert an antitumor immune response. This was seen in early triple-negative BC (TNBC) in the GeparNuevo study, where the addition of durvalumab to chemotherapy significantly improved long-term outcomes despite a nonsignificant numerical pCR increase. Furthermore, KEYNOTE-522 showed a significant improvement in pCR and EFS with neoadjuvant pembrolizumab and chemotherapy, followed by adjuvant pembrolizumab, versus placebo (pCR rates: 64.8% with pembrolizumab vs 51.2% with placebo; estimated treatment difference: 13.6%; P = .00055; EFS: hazard ratio = 0.63; P = .00031). At the 36-month time

TABLE 2. Overall Safety Profile Across the Neoadjuvant and Adjuvant Treatment Phases

| AE                        | Neoadjuvant Phase | Adjuvant Phase |
|---------------------------|-------------------|----------------|
|                           | Placebo Plus ddAC-PacPH (n = 225) | Atezolizumab Plus ddAC-PacPH (n = 226) | Placebo Plus ddAC-PacPH (n = 215) | Atezolizumab Plus ddAC-PacPH (n = 216) |
| All-grade AEs            | 225 (100)         | 226 (100)      | 183 (85.1)       | 196 (90.7)      |
| Treatment-related        | 225 (100)         | 226 (100)      | 145 (67.4)       | 163 (75.5)      |
| Grade 3-4 AEs            | 98 (43.6)         | 117 (51.8)     | 36 (16.7)        | 52 (24.1)       |
| Treatment-related        | 95 (42.2)         | 107 (47.3)     | 21 (9.8)         | 29 (13.4)       |
| Grade 5 AEs              | 0                 | 4 (1.8)        | 0                | 1 (0.5)         |
| Treatment-related        | 0                 | 2 (0.9)        | 0                | 0               |
| Serious AEs              | 30 (13.3)         | 44 (19.5)      | 18 (8.4)         | 24 (11.1)       |
| Treatment-related        | 24 (10.7)         | 34 (15.0)      | 7 (3.3)          | 11 (5.1)        |
| AEs leading to any treatment withdrawal | 27 (12.0) | 32 (14.2) | 25 (11.6) | 22 (10.2) |
| AE leading to atezolizumab/placebo withdrawal | 13 (5.8) | 19 (8.4) | 20 (9.3) | 21 (9.7) |
| AEs of special interest  | 138 (61.3)        | 164 (72.6)     | 92 (42.8)        | 122 (56.5)      |
| Grade 3-4                | 15 (6.7)          | 24 (10.6)      | 5 (2.3)          | 14 (6.5)        |

NOTE. Safety population. Data are No. (%). For AEs of special interest, see Table 4. Abbreviations: AE, adverse event; ddAC, dose-dense doxorubicin and cyclophosphamide; H, trastuzumab; P, pertuzumab; Pac, paclitaxel.

TABLE 3. Deaths Reported Across the Neoadjuvant and Adjuvant Treatment Phases

| Patient Status | Placebo Plus ddAC-PacPH (n = 225) | Atezolizumab Plus ddAC-PacPH (n = 226) |
|----------------|-----------------------------------|---------------------------------------|
| AEs leading to death, No. of patients (%) | 0 | 5 (2.2) |

Neoadjuvant phase

Alveolitis (day 75)*
Sepsis (day 72)
COVID-19 (day 115)
Septic shock (day 166)*

Adjuvant phase

COVID-19 (day 265)*

Disease recurrence listed as cause of death, No. of patients

3
1

Other, No. of patients

1 (primary gastric cancer)
0

Total, No. of patients (%)

4 (1.8)
6 (2.7)

NOTE. Safety population. Selected comorbidities and confounding factors were as follows: Alveolitis: 81-year-old, female, White patient with vertebral fracture complicated by pneumonia in a patient with suspected pulmonary metastasis. Sepsis: 69-year-old, female, White patient with anal fistula relapse leading to perineal ulceration and vulvar infection. Septic shock: 61-year-old, female, White patient with type 2 diabetes and urinary tract infection aggravated by severe neutropenia.

Abbreviations: AE, adverse event; ddAC, dose-dense doxorubicin and cyclophosphamide; H, trastuzumab; P, pertuzumab; Pac, paclitaxel.

*Causality assigned to study treatment by the investigator.
point, this EFS benefit with the addition of pembrolizumab was particularly observed in patients without a pCR (67.4% v 56.8%) versus those who did achieve a pCR (94.4% v 92.5%). These results may challenge the surrogacy of pCR as an end point when evaluating the long-term benefit of cancer immunotherapy in EBC and argue for powering studies for long-term survival end points. Ongoing studies in HER2-positive EBC, such as the adjuvant ASTEFANIA (ClinicalTrials.gov identifier: NCT04873362) and neoadjuvant/adjuvant APTneo (ClinicalTrials.gov identifier: NCT03595592) trials, may clarify the role of immunotherapy combined with different HER2-targeted therapies as they are powered for long-term efficacy end points.

Consistent with reports suggesting a prognostic role for PD-L1 expression in BC, patients with PD-L1-positive tumors in IMpassion050 demonstrated higher pCR rates than those with PD-L1–negative tumors. Conversely, no pCR benefit of adding atezolizumab to PH and chemotherapy was observed in patients with PD-L1–positive tumors. This was surprising given that, in PANACEA, pembrolizumab and trastuzumab showed durable clinical benefit in patients with PD-L1–positive, trastuzumab-resistant, HER2-positive advanced BC; with significantly greater TIL levels in objective responders and those with disease control (despite small sample sizes). Furthermore, KATE2 showed a possible survival advantage by increasing PFS and OS with the addition of atezolizumab to ado-trastuzumab emtansine for patients with PD-L1–positive tumors previously treated with a taxane and trastuzumab, although the exploratory nature of this subgroup analysis means confirmation of the results is

### TABLE 4. Specific AE Summary in the Neoadjuvant and Adjuvant Treatment Phases

| AE                                      | Neoadjuvant Phase | Adjuvant Phase |
|-----------------------------------------|-------------------|----------------|
|                                         | Placebo Plus ddAC-PacPH (n = 225) | Atezolizumab Plus ddAC-PacPH (n = 226) |
| All-grade AEs with > 5% difference between treatment groups |                    |                |
| Fatigue                                 | 30 (13.3)         | 54 (23.9)      |
| Vomiting                                | 49 (21.8)         | 73 (32.3)      |
| Hypothyroidism                          | 6 (2.7)           | 28 (12.4)      |
| Rash                                    | 29 (12.9)         | 51 (22.6)      |
| ALT increased                           | 46 (20.4)         | 63 (27.9)      |
| Hyperthyroidism                         | 0                 | 15 (6.6)       |
| Asthenia                                | 76 (33.8)         | 91 (40.3)      |
| AST increased                           | 33 (14.7)         | 46 (20.4)      |
| Grade 3-4 AEs with > 2% difference between treatment groups |                    |                |
| Febrile neutropenia                     | 3 (1.3)           | 12 (5.3)       |
| Neutropenia                             | 41 (18.2)         | 36 (15.9)      |
| Neutrophil count decreased              | 18 (8.0)          | 23 (10.2)      |
| WBC count decreased                     | 4 (1.8)           | 9 (4.0)        |

NOTE. Safety population. Data are No. (%).

Abbreviations: AE, adverse event; ddAC, dose-dense doxorubicin and cyclophosphamide; H, trastuzumab; P, pertuzumab; Pac, paclitaxel.

aNumber of patients with immune-mediated hepatitis (diagnosis): three (1.3%), three (1.3%), one (0.5%), and one (0.5%).
required. Nonetheless, there is increasing evidence from neoadjuvant trials of early TNBC that PD-L1 status may not be a predictor of benefit from checkpoint inhibitor therapy in the early setting, and other additional factors, such as induction of an immune response or enrichment of TILs, may be more important. In the preliminary results from the NeoTRIP trial of neoadjuvant atezolizumab plus carboplatin/nab-paclitaxel in TNBC, atezolizumab did not significantly increase pCR rate versus placebo in the overall population; atezolizumab increased pCR by >10% only in immune-rich groups (PD-L1-positive and TIL-high disease).

Similar to the results observed with TIL and PD-L1-positive populations in IMpassion050, no other biomarker showing an increased treatment benefit from atezolizumab versus placebo was identified. As observed previously, patients with tumors either hormone receptor-positive, HER2 IHC 2+, or PIK3CA-mutated tended to have lower pCR rates in IMpassion050, compared with those with hormone receptor-negative, HER2 IHC 3+, or PIK3CA-wild-type tumors, respectively, potentially reflecting lower addiction to the HER2 pathway and/or intrinsic resistance to anti-HER2 therapies. However, it is important to note the small sample size of some of these subgroups, limiting interpretation of the results.

In IMpassion050, the overall safety profile was consistent with the known profile for atezolizumab in combination studies. Nonetheless, five fatal AEs occurred (all in the atezolizumab arm), two of which were considered treatment-related by the investigator (alveolitis and septic shock), and two were attributed to COVID-19. This imbalance in deaths with atezolizumab seems to emerge upon combination with an intense cytotoxic regimen, unlike what has been observed in combination with single-agent chemotherapy. This emphasizes the need for careful patient monitoring and AE management. The added toxicity of cancer immunotherapies makes the demonstration of a clear survival advantage paramount, particularly in a curative setting such as EBC. Most AESIs were grade 1-2; however, some, such as immune-related endocrine dysfunctions (eg, hypothyroidism and adrenal insufficiency), are chronic and warrant careful patient selection in a curative setting.

IMpassion050, as a large clinical data set with ongoing correlative analyses with tumor- and immune-related features, may help to identify patients most likely to benefit from cancer immunotherapy in HER2-positive EBC. However, EFS and OS were secondary endpoints only, and IMpassion050 was not powered for long-term outcomes, which limits understanding of the long-term impact of atezolizumab in this indication. Follow-up is ongoing and may be hypothesis-generating with regards to the long-term benefit of atezolizumab in EBC.

In conclusion, in the IMpassion050 primary analysis, atezolizumab and neoadjuvant ddAC-PacPH for high-risk, HER2-positive EBC did not increase pCR rates versus placebo in either the ITT or the PD-L1-positive population. Current neoadjuvant SOC for HER2-positive EBC (PH and chemotherapy) remains valid; further data are needed to clarify the role of cancer immunotherapy in this setting.

AFFILIATIONS
1Cantonal Hospital, Breast Center St Gallen, St Gallen, Switzerland
2University Hospital, Ulm, Germany
3Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil
4Department of Breast Oncology, Tokai University School of Medicine, Isehara, Japan
5Breast Cancer Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Giwice Branch, Giwice, Poland
6Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
7UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
8Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil
9SBIH Moscow Clinical Scientific and Practical Center named after A.S. Logino of DHM, Moscow, Russia
10Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
11Product Development Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland
12Product Development Safety, Roche Products Limited, Welwyn Garden City, United Kingdom
13Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
14Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

CORRESPONDING AUTHOR
Jens Huober, MD, Cantonal Hospital, Breast Center St Gallen, St Gallen, 9007, Switzerland +41 71 494 1888; e-mail: jens.huober@kssg.ch.

PRIOR PRESENTATION
Presented in part at the European Society for Medical Oncology Virtual Plenary 2021, June 17-18, 2021.

SUPPORT
The study was sponsored by F. Hoffmann-La Roche Ltd.

CLINICAL TRIAL INFORMATION
NCT03726879

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.21.02772.

DATA SHARING STATEMENT
For eligible studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli (https://vivli.org/ourmember/roche/). For up-to-date details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: https://go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked because of a potential increase in risk of patient reidentification.
AUTHOR CONTRIBUTIONS
Conception and design: Jens Huober, Carlos H. Barrios, Naoki Niikura, Shannon L. Huggins-Puhalla, Chiara Lambertini, Hong Zhang

Provision of study materials or patients: Jens Huober, Michael Jarzab, Yuan-Ching Chang, José Pedrini, Lyudmila Zhukova, Volkm Henschel, Nino Gochitasvili, Chiara Lambertini, Hong Zhang

Collection and assembly of data: Carlos H. Barrios, Naoki Niikura, Michael Jarzab, Yuan-Ching Chang, José Pedrini, Lyudmila Zhukova, Volkm Graupner, Volkm Henschel, Nino Gochitasvili, Chiara Lambertini, Hong Zhang

Data analysis and interpretation: Jens Huober, Carlos H. Barrios, Naoki Niikura, Michal Jarzab, Shannon L. Huggins-Puhalla, Volkm Graupner, Daniel Eiger, Volkm Henschel, Nino Gochitasvili, Chiara Lambertini, Eleonora Restuccia, Hong Zhang

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT
The authors thank the patients and their families, participating study investigators, and clinical sites. Research support in the form of third-party medical writing assistance, including the initial draft, was provided by Stephen Salem, BSc (Health Interactions, Manchester, UK; funded by F. Hoffmann-La Roche Ltd).

REFERENCES
1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987

2. Costa RLB, Czerniecki BJ: Clinical development of immunotherapies for HER2+ breast cancer: A review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer 6:10, 2020

3. Gianni L, Pienkowski T, Im YH, et al: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17:791-800, 2016

4. Swain SM, Miles D, Kim SB, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519-530, 2020

5. Cardoso F, Krynides S, Ohno S, et al: Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1194-1220, 2019

6. National Comprehensive Cancer Network (NCCN): NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer. Version 4. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

7. Korde LA, Somerfield MR, Carey LA, et al: Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485-1505, 2021

8. Burstein HJ, Curiogiono G, Loibl S, et al: Estimating the benefits of therapy for early stage breast cancer in the St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30:1541-1557, 2019

9. von Minckwitz G, Huang CS, Mano MS, et al: Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617-628, 2019

10. Cortazar P, Zhang L, Uncch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:164-172, 2014

11. Spring LM, Fell G, Arfe A, et al: Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res 26:2808-2848, 2020

12. Waldman AD, Fritz JM, Lenardo MJ: A guide to cancer immunotherapy. From T cell basic science to clinical practice. Nat Rev Immunol 20:651-668, 2020

13. Denkert C, von Minckwitz G, Darb-Esfahani S, et al: Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant chemotherapy. Lancet Oncol 19:40-50, 2018

14. Ignatiadis M, Van den Eynden G, Roberto S, et al: Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTO trial. JAMA Oncol 1:448-454, 2015

15. Piccart M, Procter M, Fumagalli D, et al: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol 39:1448-1457, 2021

16. Stagg J, Loi S, Divisekera U, et al: Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti–CD137 mAb therapy. Proc Natl Acad Sci U S A 108:7142-7147, 2011

17. Nagai Y, Tsuchiya H, Runkle EA, et al: Disabling of the erbB pathway followed by IFN–γ modifies phenotype and enhances genotoxic eradication of breast tumors. Cell Rep 12:2049-2059, 2015

18. Müller P, Kreuzaler M, Khan T, et al: Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med 7:315ra188, 2015

19. Herbst RS, Jia C, Kowanetz M, et al: Molecular correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014

20. Emens LA, Esteva FJ, Beresford M, et al: Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): A phase 2, multicentre, randomised, double-blind, trial. Lancet Oncol 21:1283-1295, 2020

21. Schmid P, Adams S, Rugo HS, et al: Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 395:1835-1844, 2020

22. Loibl S, Schneeweiß A, Huober JB, et al: Durvalumab improves long-term outcome in TNBC: Results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 39, 2021 (abstr 506)

23. Schmid P, Cortes J, Dent R, et al: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage triple-negative breast cancer. Ann Oncol 32, 2021 (abstr VP-2021)
29. Mittendorf EA, Zhang H, Barrios CH, et al: Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial. Lancet 396:1090-1100, 2020

30. Bianchini G, Huang C, Egle D, et al: Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol 31, 2020 (abstr LBA13)

31. Loibl S, Untch M, Burchardi N, et al: A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: Clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30:1279-1288, 2019

32. Loibl S, Giobbie-Hurder A, Gomboa S, et al: Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): A single-arm, multicentre, phase 1b-2 trial. Lancet Oncol 20:371-382, 2019

33. Schmid P, Cortes J, Pusztai L, et al: Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810-821, 2020

34. Loibl S, Schneeweiss A, et al: Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: A subanalysis of data from the randomized phase III GeparSepto trial. Ann Oncol 28:497-504, 2017

35. Meisel JL, Zhao J, Suo A, et al: Clinicopathologic factors associated with response to neoadjuvant anti-HER2-directed chemotherapy in HER2-positive breast cancer. Clin Breast Cancer 20:19-24, 2020

36. Zhao J, Krishnamurti U, Zhang C, et al: HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathol Res Pract 216:153155, 2020

37. Lillemoe TJ, Rendi M, Tsai ML, et al: HER2 testing characteristics can predict residual cancer burden following neoadjuvant chemotherapy in HER2-positive breast cancer. Int J Breast Cancer 2021:6684629, 2021

38. Schneeweiss A, Chia S, Hegg R, et al: Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: An exploratory analysis of the TRYPHAENA study. Breast Cancer Res 16:R73, 2014

39. de Haas SL, Hurvitz SA, Martin M, et al: Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC). Cancer Res 77, 2017 (abstr P6-07-09)

40. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007

41. Loibl S, Majewski I, Guarneri V, et al: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol 27:1519-1525, 2016

42. Loibl S, von Minckwitz G, Schneeweiss A, et al: PIK3CA mutations are associated with lower rates of pathologic complete response to anti–human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 32:3212-3220, 2014

43. Schmid P, Rugo HS, Adams S, et al: Pembrolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:44-59, 2020

44. Hamilton EP, Kaklamani V, Falkson C, et al: Pembrolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer: A phase 1b study. Cancer Res 80, 2020 (abstr PD1-05)

45. Cortes J, Cescon DW, Rugo HS, et al: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396: 1817-1828, 2020

46. Miles D, Gilgorov J, André F, et al: Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:994-1004, 2021
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Jens Huober
Honoraria: Roche, Lilly, Pfizer, Celgene, MSD Oncology, AstraZeneca, AbbVie, Novartis, Seagen, Daiichi Sankyo/AstraZeneca, Gilead Sciences, Eisai
Consulting or Advisory Role: Novartis, Roche, Pfizer, Lilly, Celgene, AstraZeneca, AbbVie, Eisai, MSD Oncology, Hexal, Daiichi Sankyo/Astra Zeneca
Research Funding: Novartis (Inst), Celgene (Inst), Hexal, Lilly (Inst), Roche
Travel, Accommodations, Expenses: Novartis, Roche, Pfizer, Celgene, Daiichi Sankyo
Uncompensated Relationships: German Breast Group

Carlos H. Barrios
Stock and Other Ownership Interests: MedSIR, Turmini
Honoraria: Novartis, Roche/Genentech, Pfizer, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, Eisai, MSD, Lilly, Bayer, AstraZeneca, Zodiac Pharma
Consulting or Advisory Role: Boehringer Ingelheim, Roche/Genentech, Novartis, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Libbs, MSD Oncology, United Medical, Lilly
Research Funding: Pfizer (Inst), Novartis (Inst), Amgen (Inst), AstraZeneca (Inst), Boehringer Ingelheim (Inst), GlaxoSmithKline (Inst), Roche/Genentech (Inst), Lilly (Inst), Sanofi (Inst), Taiho Pharmaceutical (Inst), Mylan (Inst), Merrimack (Inst), Merck (Inst), AbbVie (Inst), Astellas Pharma (Inst), Biogenic (Inst), Bristol Myers Squibb (Inst), Daiichi Sankyo (Inst), Abraxis BioScience (Inst), AB Science (Inst), Asana Biosciences (Inst), Medivation (Inst), Exelixis (Inst), ImClone Systems (Inst), LEO Pharma (Inst), Millennium (Inst), Janssen (Inst), Clinica Atlantis (Inst), INC Research (Inst), Halozyme (Inst), Covance (Inst), Celgene (Inst), inVentiv Health (Inst), Shanghai Henlius Biotech (Inst), Polyphor (Inst), PharmaMar (Inst)
Travel, Accommodations, Expenses: Roche/Genentech, Novartis, Pfizer, BMS Brazil, AstraZeneca, MSD Oncology, Lilly

Naoki Niikura
Honoraria: Chugai Pharma, AstraZeneca, Eisai, Novartis, Daiichi Sankyo/UCB Japan, Nippon Kayaku, Lilly Japan, MSD, Pfizer, Nihon Medi-Physics, Taiho Pharmaceutical, Takeda, Kyowa Kirin
Consulting or Advisory Role: Roche, Pfizer, AstraZeneca, MSD, Daiichi Sankyo
Research Funding: Chugai Pharma, Nihon Medi-Physics, Daiichi Sankyo, Eisai, Pfizer (Inst), Nippon Kayaku (Inst), Kyowa Kirin, Takeda, Lilly Japan (Inst), Roche

Michal Jarząb
Honoraria: Roche, Novartis, Pfizer
Consulting or Advisory Role: Pfizer, Novartis, Lilly, Roche
Speakers' Bureau: Exact Sciences, Roche, Novartis, Pfizer
Research Funding: Roche
Travel, Accommodations, Expenses: Pfizer, Lilly, Roche, Novartis

Yuan-Ching Chang
Research Funding: Roche

Shannon L. Huggins-Puhalla
Consulting or Advisory Role: AbbVie, Roche/Genentech
Research Funding: AbbVie (Inst), Pfizer (Inst), AstraZeneca (Inst)

José Pedrini
Research Funding: Roche

Lyudmila Zhukova
Honoraria: AstraZeneca, Novartis, Lilly
Consulting or Advisory Role: Novartis
Research Funding: Roche

Vilma Graupner
Employment: Roche
Stock and Other Ownership Interests: Roche

Daniel Eiger
Employment: Roche
Stock and Other Ownership Interests: Roche
Research Funding: Novartis

Volkmar Henschel
Employment: Roche

Nino Gochitashvili
Employment: Roche Products Limited
Stock or Other Ownership Interests: Roche

Chiara Lamberti
Employment: Roche

Eleonora Restuccia
Employment: Roche
Stock and Other Ownership Interests: Roche

Hong Zhang
Consulting or Advisory Role: Roche/Genentech
Research Funding: Roche

No other potential conflicts of interest were reported.